Literature DB >> 27578220

Association between adjunctive metformin therapy in young type 1 diabetes patients with excess body fat and reduction of carotid intima-media thickness.

Paweł Burchardt, Agnieszka Zawada, Jolanta Kaczmarek, Justyna Marcinkaniec, Henryk Wysocki, Bogna Wierusz-Wysocka, Marian Grzymisławski, Janusz Rzeźniczak, Dorota Zozulińska-Ziółkiewicz, Dariusz Naskręt.   

Abstract

INTRODUCTION    Lipoprotein-associated phospholipase A2 (Lp-PLA2) and cholesteryl ester lipase (CEL) may oxidize low-density lipoproteins (oxLDL). OBJECTIVES    The aim of the study was to determine the influence of metformin on the metabolism of atherogenic lipid fractions in relation to Lp-PLA2 and CEL levels, as well as assess consequent improvement in the intima-media thickness (IMT) of the common carotid artery in young type 1 diabetes patients with excess body fat. PATIENTS AND METHODS    It was an open-label randomized clinical trial that lasted 6 months. It included a total of 84 people with metabolic decompensation (glycated hemoglobin >7.5%, >58.5 mmol/mol) of diabetes. Adjunctive metformin therapy (in addition to insulin) was administered in 42 patients, and the remaining 42 patients received insulin alone. Glycated low-density lipoproteins (LDLs), oxLDL, Lp-PLA2, and CEL were assessed by commercially available enzyme-linked immunosorbent assay kits. Cartoid IMT was measured using the Carotid Analyser for Research tool. Biochemical analyses were performed using routine laboratory techniques. RESULTS    The reduction of mean carotid IMT was observed in young type 1 diabetic adults treated additionally with metformin (0.6 ±0.1 cm vs 0.53 ±0.1 cm; P = 0.002). This effect was probably due to weight reduction (90 ±16 kg vs 87 ±15 kg, P = 0.054) and the decrease in atherogenic glycated LDL levels (1.5 ±0.5 mg/dl vs 1.6 ±1.046 mg/dl, P = 0.006). No such correlations were observed in patients treated with insulin alone. Additionally, in patients receiving metformin, glycated LDL levels were inversely correlated with Lp-PLA2 levels (r = -0.31, P <0.05). CONCLUSIONS    Additional use of metformin in young type 1 diabetic patients with excess body fat leads to a significant reduction of mean IMT in the common carotid artery. Concentrations of CEL and Lp-PLA2 were significantly increased in both study arms despite improved glucose metabolism.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27578220     DOI: 10.20452/pamw.3527

Source DB:  PubMed          Journal:  Pol Arch Med Wewn


  5 in total

1.  Lipoprotein-associated phospholipase A2 activity in obese adolescents with and without type 2 diabetes.

Authors:  Julia Seyfarth; Thomas Reinehr; Annika Hoyer; Christina Reinauer; Christina Bächle; Beate Karges; Ertan Mayatepek; Michael Roden; Sabine E Hofer; Susanna Wiegand; Joachim Woelfle; Wieland Kiess; Joachim Rosenbauer; Reinhard W Holl; Thomas Meissner
Journal:  J Inherit Metab Dis       Date:  2017-10-13       Impact factor: 4.982

Review 2.  A Review of Insulin Resistance in Type 1 Diabetes: Is There a Place for Adjunctive Metformin?

Authors:  Gagan Priya; Sanjay Kalra
Journal:  Diabetes Ther       Date:  2017-11-14       Impact factor: 2.945

Review 3.  Is the Retinol-Binding Protein 4 a Possible Risk Factor for Cardiovascular Diseases in Obesity?

Authors:  Anna Maria Rychter; Marzena Skrzypczak-Zielińska; Aleksandra Zielińska; Piotr Eder; Eliana B Souto; Agnieszka Zawada; Alicja Ewa Ratajczak; Agnieszka Dobrowolska; Iwona Krela-Kaźmierczak
Journal:  Int J Mol Sci       Date:  2020-07-23       Impact factor: 5.923

4.  Increased efficacy of metformin corresponds to differential metabolic effects in the ovarian tumors from obese versus lean mice.

Authors:  Jianjun Han; Weiya Z Wysham; Yan Zhong; Hui Guo; Lu Zhang; Kim M Malloy; Hallum K Dickens; Gene Huh; Douglas Lee; Liza Makowski; Chunxiao Zhou; Victoria L Bae-Jump
Journal:  Oncotarget       Date:  2017-09-08

Review 5.  Obesity and diabetes-Not only a simple link between two epidemics.

Authors:  Agata Chobot; Katarzyna Górowska-Kowolik; Magdalena Sokołowska; Przemysława Jarosz-Chobot
Journal:  Diabetes Metab Res Rev       Date:  2018-07-17       Impact factor: 4.876

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.